case_images: PMC3917539_01
case_images: Grade 3 skin toxicity secondary to docetaxel.
case_images: 1752-1947-8-6-1.jpg
case_images: PMC3917539_01_1752-1947-8-6-1.jpg
case_images: F1
case_images: After cycle 1, the patient developed grade 3 skin toxicity (with a predominance of erythrodysesthesia on the soles of her feet and on the palms and dorsa of her hands), grade 3 arthralgia and myalgia, and grade 2 asthenia (Figure 1).
case_images: Improvement of skin toxicity during treatment with nanoparticle albumin-bound paclitaxel.
case_images: 1752-1947-8-6-2.jpg
case_images: PMC3917539_01_1752-1947-8-6-2.jpg
case_images: F2
case_images: Standard paclitaxel would have required a dose reduction or further delays in treatment (Figure 2).